US FDA Focused On Vulnerable Populations As Cosmetic Risk Assessment Protocol Develops

The agency’s recent request for contractor quotes cites infants and children, people of color, and immunosuppressed individuals among users whose “unique biological characteristics” could require special consideration in the evaluation of cosmetic ingredients. The FDA also is interested in accounting for unique physicochemical aspects of ingredients such as engineered nanomaterials.